LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH

Main measures

• The primary objective will be measured on upper limbs, based the following endpoint: proportion of patients with upper limb disability progression, defined as the proportion of patients with ≥20% worsening in 9-HPT score confirmed for at least 24 weeks, from baseline to Week 192.

  Disability progressionArm and hand function

• C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cel

  Phase 1 / Phase 2 · Not yet recruiting

  Still running

• IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multi

  Phase 1 · Paused

  Still running

• The Effect of Rituximab on Cognitive and Hand Functions in Secondary P

  Phase 2 · Recruiting

  Still running

• Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With

  Completed

  No results found

• Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

  Completed

  No results found

• A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Infla

  Phase 4 · Withdrawn

  Stopped

1. Oct 2026In scope changed from true to false

1. Started

   Dec 2021